Associations between SLFN11 levels, clinicopathological features, and survival were analyzed.<h4>Results</h4>In the neoadjuvant cohort, SLFN11 expression correlated with pathological tumor regression after chemotherapy alone (rho = 0.73, p = 0.016) and chemotherapy ± radiotherapy (rho = 0.62, p = 0.011). The gene discussed is SLFN11; the disease is neoplasm.